chloroquin
togeth
hydroxyl
deriv
hydroxychloroquin
initi
use
antimalari
agent
also
use
treatment
autoimmun
diseas
rheumatoid
arthriti
system
lupu
erythematosu
sle
chloroquin
hydroxychloroquin
approv
treatment
sle
shown
reduc
frequenc
diseas
flare
particularli
lupu
nephriti
contribut
mainten
remiss
prolong
onset
diseas
reduc
risk
beyond
immunomodulatori
effect
sle
agent
also
shown
protect
thrombot
improv
glucos
lipid
profil
prevent
renal
appar
result
reduc
cardiovascular
risk
sle
independ
risk
factor
ultim
increas
rate
surviv
report
sle
patient
take
antimalari
antimalari
agent
inexpens
especi
compar
treatment
use
recent
sle
patient
also
good
overal
toler
profil
except
risk
retin
toxic
date
antimalari
agent
reliabl
link
increas
incid
infect
known
occur
use
immunosuppress
drug
context
surprisingli
recent
nest
studi
aim
identifi
factor
predict
infecti
report
sle
patient
treat
antimalari
agent
lower
risk
major
infect
odd
ratio
ci
wherea
prednison
treatment
ci
lung
involv
ci
increas
risk
interestingli
median
dose
prednison
patient
major
infect
mg
per
day
mg
per
day
dose
increas
led
increas
infect
risk
cyclophosphamid
exposur
overt
lupu
nephriti
associ
enhanc
infect
risk
studi
probabl
insuffici
number
patient
includ
although
studi
ruizirastorza
limit
inclus
case
sle
control
show
risk
major
infect
time
lower
patient
treat
antimalari
agent
effect
antimalari
consist
observ
two
previou
studi
one
retrospect
studi
patient
lupu
nephriti
identifi
lower
frequenc
infect
among
patient
previous
treat
antimalari
anoth
studi
patient
found
hydroxychloroquin
treatment
led
lower
risk
major
infect
give
ci
compar
studi
ruizirastorza
partli
correct
diseas
activ
although
prospect
studi
need
confirm
data
assess
valu
antimalari
agent
especi
hydroxychloroquin
requir
reevalu
underli
mechan
action
beyond
benefit
clinic
prevent
lupu
flare
increas
patient
surviv
prevent
sever
organ
damag
thrombosi
bone
mass
loss
possibl
use
pregnant
patient
indic
reduc
major
infect
might
shed
new
light
antimalari
agent
magic
therapeut
bullet
noteworthi
similar
reduct
infect
hydroxychloroquin
use
observ
patient
rheumatoid
arthriti
suggest
reduct
infect
might
restrict
usual
key
factor
consid
immunosuppress
therapi
treatment
patient
sle
substanti
increas
risk
infect
immunosuppress
drug
notabl
steroid
well
sle
activ
presenc
lupu
nephriti
low
serum
complement
level
shown
increas
rate
infect
although
intim
interrelationship
diseas
activ
choic
therapi
intens
critic
system
autoimmun
diseas
one
rule
clinic
practic
say
intens
therapi
patient
activ
diseas
increas
risk
infect
antimalari
agent
abl
break
rule
even
data
ruizistorza
et
confirm
clinic
prospect
studi
still
left
uncertainti
uniqu
underli
immunomodulatori
antiinfect
effect
antimalari
agent
origin
use
antiparasit
agent
antimalari
drug
also
shown
antimicrobi
least
vitro
bacteria
tropheryma
whippelii
staphylococcu
aureu
legionella
pneumophila
mycobacterium
speci
salmonella
typhi
escherichia
coli
borrelia
burgdorferi
virus
includ
hiv
sever
acut
respiratori
syndrom
sar
coronaviru
remark
combin
immunomodulatori
effect
effect
varieti
microb
noteworthi
indic
hitherto
unknown
pathway
immun
intervent
protect
respect
two
major
concept
postul
explain
mechan
action
antimalari
agent
first
alkalin
phagolysosom
kill
intracellular
bacteria
fungi
second
blockad
sever
step
viral
entri
protein
glycosyl
prevent
spread
antibacteri
antifung
effect
antimalari
agent
appear
link
interfer
antigen
present
mediat
phdepend
iron
depriv
increas
phagolysosom
ph
ultim
lead
reduc
immun
system
activ
inhibit
growth
intracellular
moreov
basic
intracellular
ph
induc
antimalari
agent
could
antivir
effect
result
blockad
hydrolas
posttransl
modif
includ
inhibit
glycosyl
newli
synthes
protein
notabl
glycosyl
inhibit
might
lead
interact
chloroquin
sugarmodifi
enzym
glycosyltransferas
could
account
effect
number
process
sialicacid
depend
includ
intracellular
well
extracellular
function
exampl
bind
surfac
receptor
third
rather
appeal
concept
hypothes
interfer
innat
immun
activ
block
tolllik
receptor
tlr
could
respons
number
effect
antimalari
agent
thu
antimalari
agent
interfer
intracellular
recognit
nucleicacidbind
harbor
intracellular
compart
block
activ
interferon
sle
sinc
tlr
recognit
also
involv
protect
infect
tempt
idea
antimalari
agent
lead
promin
tlr
inhibit
chang
intracellular
ph
despit
report
valuabl
clinic
effect
antimalari
agent
sle
still
need
addit
confirm
clinic
studi
well
moredetail
basic
studi
deciph
mechan
action
sinc
patient
sle
treat
antimalari
agent
avail
data
drug
demand
reconsider
pleiotrop
effect
sle
patient
contraind
ultim
better
understand
individu
effect
antimalari
agent
could
pave
way
innov
drug
combin
immunomodulatori
antiinfect
potenc
even
provid
new
etiopathogen
insight
sle
